AdoXLong Platform

About Adocia

Adocia is a clinical-stage biotechnology company focused on developing innovative formulations and delivery systems for metabolic diseases, primarily diabetes and obesity. The company's strategy is built on four proprietary technology platforms (BioChaperone®, AdoShell®, AdOral®, AdoXLong) designed to enhance the efficacy and delivery of peptides, proteins, and cell therapies. Key achievements include advancing a Phase 3 ultra-rapid insulin and securing partnerships with major pharmaceutical firms like Eli Lilly and Tonghua Dongbao. Adocia's business model involves licensing out its validated assets post-proof-of-concept to global partners for development and commercialization.

Therapeutic Areas